Business
Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2025 Results
Lead program VMT-α-NET in neuroendocrine tumors continues to demonstrate a favorable tolerability profile with durable disease control and deepening of tumor response with longer follow-up, as reported at ASCO-GI 2026VMT-α-NET study on track to achieve nearly one year of follow-up in all 46 patients in Cohort 2 by mid-2026; analysis to inform patient selection strategy ongoingData across all dose levels in the VMT-α-NET program provide development optionality and support the build-out of a robus
About this update from Perspective Therapeutics, Inc.
[{"type":"image","alt":"Perspective Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Perspective Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":63,"url":"https://media.zenfs.com/en/globenewswire.com/a27565ee8edf0640bed1250d2c58f3a9"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/QSFbVndZiJCez3FgWA5yTA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTg4O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/a27565ee8edf0640bed1250d2c58f3a9","width":300,"height":63}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Lead program VMT-α-NET in neuroendocrine tumors continues to demonstrate a favorable tolerability profile with durable disease control and deepening of tumor response with longer follow-up, as reported at ASCO-GI 2026","length":217,"tagName":"p"}]},{"val":[{"type":"text","content":"VMT-α-NET study on track to achieve nearly one year of follow-up in all 46 patients in Cohort 2 by mid-2026; analysis to inform patient selection strategy ongoing","length":162,"tagName":"p"}]},{"val":[{"type":"text","content":"Data across all dose levels in the VMT-α-NET program provide development optionality and support the build-out of a robust clinical evidence package for submission for presentation to more medical conferences and regulatory engagement in 2026","length":242,"tagName":"p"}]},{"val":[{"type":"text","content":"Clinical updates for all three clinical programs are expected to be submitted for presentation at medical conferences throughout 2026","length":133,"tagName":"p"}]},{"val":[{"type":"text","content":"Cash, cash equivalents and short-term investments of approximately $145M as of December 31, 2025, together with subsequent equity offering (net proceeds of ~$164 million), expected to be sufficient to fund current planned clinical milestones and operational investments into late 2027","length":284,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":1038,"olType":false},{"type":"text","content":"SEATTLE, March 16, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today provided a business update and announced full year results for the year ended December 31, 2025.",...